Oragenics Inc

ASE:OGEN   2:07:41 PM EDT
0.24
0.00 (+1.98%)
Products

Oragenics Reports Preliminary Data For Intranasal COVID-19 Vaccine Candidate

Published: 08/24/2022 11:13 GMT
Oragenics Inc (OGEN) - Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal Covid-19 Vaccine Candidate.
Oragenics Inc - N T-cov2-1 Preliminary Data Supports Regulatory Filings for Phase 1 Studies.
Oragenics Inc - Intranasal Administration Elicits Immune Responses.
Oragenics Inc - Expect to Initiate Our Phase 1 Clinical Study by Early 2023.